<description>In our season six finale, we dive deeper into how artificial intelligence (AI) is shaping the future of drug discovery and scientific research. With remarkable scale and speed, AI models parse through complex datasets and confirm or generate hypotheses, which can help scientists accelerate R&amp;D. In this episode, co-host Danielle Mandikian welcomes Aviv Regev, Head of gRED, and Jure Leskovec, Professor of Computer Science at Stanford University, to talk about foundation models and autonomous agents. Together, they explore the opportunities and challenges of applying AI in drug discovery, including balancing innovation with scientific rigor and the evolving role of scientists. They also discuss how AI is reshaping the future of research — from building more biologically meaningful models to advancing agent-based systems and lab automation. 

Read the full text transcript at www.gene.com/stories/foundation-models-and-agents</description>

In our season six finale, we dive deeper into how…

In our season six finale, we dive deeper into how artificial intelligence (AI) is shaping the future of drug discovery and scientific research. With remarkable scale and speed, AI models parse through complex datasets and confirm or generate hypotheses, which can help scientists accelerate R&D. In this episode, co-host Danielle Mandikian welcomes Aviv Regev, Head of gRED, and Jure Leskovec, Professor of Computer Science at Stanford University, to talk about foundation models and autonomous agents. Together, they explore the opportunities and challenges of applying AI in drug discovery, including balancing innovation with scientific rigor and the evolving role of scientists. They also discuss how AI is reshaping the future of research — from building more biologically meaningful models to advancing agent-based systems and lab automation. 

Read the full text transcript at www.gene.com/stories/foundation-models-and-agents

S6E07: Foundation Models and Agents

<description>From our first breath, the air we breathe and our genes shape how our lungs function. It’s a complex interplay we began exploring in our season four episode “Take A Deep Breath: Treating Asthma.” Today, we’re branching out to discuss lung biology and the diseases that make it difficult to breathe. In this episode, co-host Maria Wilson speaks with Dorothy Cheung, Executive Group Medical Director, and Daniel Lafkas, Senior Principal Scientist, Translational Discovery Research, Roche, to understand how conditions with unmet need like chronic bronchitis and emphysema disrupt lung function. They discuss the challenges to treating lung diseases and explore promising approaches, from cutting-edge imaging technologies that help researchers uncover early drivers of disease, to treatments aimed at stopping the loss of lung function and restoring it.

Read the full text transcript at www.gene.com/stories/decoding-lung-disease</description>

From our first breath, the air we breathe and our…

From our first breath, the air we breathe and our genes shape how our lungs function. It’s a complex interplay we began exploring in our season four episode “Take A Deep Breath: Treating Asthma.” Today, we’re branching out to discuss lung biology and the diseases that make it difficult to breathe. In this episode, co-host Maria Wilson speaks with Dorothy Cheung, Executive Group Medical Director, and Daniel Lafkas, Senior Principal Scientist, Translational Discovery Research, Roche, to understand how conditions with unmet need like chronic bronchitis and emphysema disrupt lung function. They discuss the challenges to treating lung diseases and explore promising approaches, from cutting-edge imaging technologies that help researchers uncover early drivers of disease, to treatments aimed at stopping the loss of lung function and restoring it.

Read the full text transcript at www.gene.com/stories/decoding-lung-disease

S6E06: Decoding Lung Disease

<description>Cell therapy holds immense potential to transform the way we treat conditions in oncology, ophthalmology, autoimmune disorders, and a wide range of other therapeutic areas. But how do these engineered cells work, and how do scientists ensure they are safe and function as intended? In this episode, co-host Danielle Mandikian sits down with Todd McDevitt, Head of Cell Therapy, to discuss how cell therapies operate within the body, the challenges researchers face in this field, and the advancements needed to unlock their full potential for patients.

Read the full text transcript at www.gene.com/stories/cells-at-work</description>

Cell therapy holds immense potential to transform…

Cell therapy holds immense potential to transform the way we treat conditions in oncology, ophthalmology, autoimmune disorders, and a wide range of other therapeutic areas. But how do these engineered cells work, and how do scientists ensure they are safe and function as intended? In this episode, co-host Danielle Mandikian sits down with Todd McDevitt, Head of Cell Therapy, to discuss how cell therapies operate within the body, the challenges researchers face in this field, and the advancements needed to unlock their full potential for patients.

Read the full text transcript at www.gene.com/stories/cells-at-work

S6E05: Cells at Work

<description>Digital twins are virtual models of real-world systems that have been gaining momentum as a powerful tool in drug discovery and development. We touched on this concept last season when we covered computational advancements in drug discovery. Now, we’re taking a deeper dive into the power of digital twins. By leveraging genomics, physical health data, lab results, and other clinical datasets, digital twins allow researchers to model certain diseases, help predict treatment outcomes, and more efficiently optimize dosing strategies for clinical studies. In this episode, co-host Maria Wilson is joined by Iraj Hosseini, Distinguished Scientist and Director, gRED Development Sciences, to explore how digital twins could simulate thousands of "what if" scenarios, paving the way for faster and more patient-centric therapeutic strategies.

Read the full text transcript at www.gene.com/stories/the-power-of-digital-twins</description>

Digital twins are virtual models of real-world sy…

Digital twins are virtual models of real-world systems that have been gaining momentum as a powerful tool in drug discovery and development. We touched on this concept last season when we covered computational advancements in drug discovery. Now, we’re taking a deeper dive into the power of digital twins. By leveraging genomics, physical health data, lab results, and other clinical datasets, digital twins allow researchers to model certain diseases, help predict treatment outcomes, and more efficiently optimize dosing strategies for clinical studies. In this episode, co-host Maria Wilson is joined by Iraj Hosseini, Distinguished Scientist and Director, gRED Development Sciences, to explore how digital twins could simulate thousands of "what if" scenarios, paving the way for faster and more patient-centric therapeutic strategies.

Read the full text transcript at www.gene.com/stories/the-power-of-digital-twins

S6E04: The Power of Digital Twins

<description>Each season we discuss new, exciting breakthroughs in cancer research. With evolving technologies enhancing how we understand and target the underlying drivers of cancer, the journey to developing more effective and safer therapies is advancing rapidly. In this episode, co-host Danielle Mandikian speaks with first-time guest Jennifer Schutzman, Executive Group Medical Director, Early Clinical Development, and returning guest Fred de Sauvage, Vice President of Research Oncology, about the innovative approaches scientists are taking to redefine cancer care. They discuss the promise of earlier detection and intervention, patient-centered treatment strategies, persistent challenges in the field, and how scientists are working to close the gap on unmet needs in cancer care. 

Read the full text transcript at www.gene.com/stories/new-frontiers-in-cancer</description>

Each season we discuss new, exciting breakthrough…

Each season we discuss new, exciting breakthroughs in cancer research. With evolving technologies enhancing how we understand and target the underlying drivers of cancer, the journey to developing more effective and safer therapies is advancing rapidly. In this episode, co-host Danielle Mandikian speaks with first-time guest Jennifer Schutzman, Executive Group Medical Director, Early Clinical Development, and returning guest Fred de Sauvage, Vice President of Research Oncology, about the innovative approaches scientists are taking to redefine cancer care. They discuss the promise of earlier detection and intervention, patient-centered treatment strategies, persistent challenges in the field, and how scientists are working to close the gap on unmet needs in cancer care. 

Read the full text transcript at www.gene.com/stories/new-frontiers-in-cancer

S6E03: New Frontiers in Cancer

From research on cancer vaccines to why we feel pain, scientists are tackling some of the biggest challenges in human biology. Want to find out what they’re working on? Pull up a stool for "Two Scientists Walk Into a Bar." Subscribe below to catch each episode as it goes live.

Two Scientists Walk Into a Bar

Details

Recent Episodes